AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|
15.1 C
New York
Monday, October 19, 2026

Tag: prevalence

newssourceFORcompanycontentinformation1releasesmarket

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders...

Vast majority of patients dosed completed the full 12-week study

Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape. 
Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness...

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...

Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrevalence

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers